Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CHFR |
| Gene Name: | CHFR |
| Protein Full Name: | E3 ubiquitin-protein ligase CHFR |
| Alias: | Checkpoint with forkhead and ring finger domains; Checkpoint with forkhead and RING finger domains protein; FLJ10796; FLJ33629; RING finger protein 196; RNF116; RNF196 |
| Mass (Da): | 73368 |
| Number AA: | 664 |
| UniProt ID: | Q96EP1 |
| Locus ID: | 55743 |
| COSMIC ID: | CHFR |
| Gene location on chromosome: | 12q24.33 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19718 |
| Percent of cancer specimens with mutations: | 0.51 |
| Gene undergoes hypermethylation: | promotor hypermethylated in a variety of cancer cell lines (esophageal, colon, lung, osteosarcoma, central nervous system, leukemic and primary tumors of the colon, lung and esophagus) and primary tumors (non-small lung carcinomas (10%), colon adenocarcin |
| Normal role description: | Ubiquitin ligase. Induces early G2/M checkpoint and delays mitosis in mitotic stress. Induces degradation of AURKA and PLK1 by ubiquitination. May polyubiquitinate HDAC1. CHFR is suggested to generate non-degrading ubiquitin-tags for protein interaction. |